Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).

The improvements seen with apremilast continued through week 24, with a mean reduction of −0.27; however, the mean change did not reach statistical significance versus placebo due to an unexpected shift in mean improvement in the placebo group between weeks 16 and 24 (−0.27 vs −0.17; P=0.168).

also in 111,027 other papers